Teva Shares Jump 9% as Innovative Drug Sales Top $1 Billion

Teva shares rose 9% after the Israeli drugmaker reported $4.142 billion in second-quarter revenue and raised its 2026 sales outlook for Austedo, Ajovy and Uzedy. The three innovative medicines generated more than $1 billion together, up 43% year over year in local-currency terms. Austedo reached $696 million, Ajovy $244 million and Uzedy $77 million, while generic-product revenue fell. Teva posted a $576 million net loss, mainly reflecting expenses tied to the Emalex acquisition, and kept its full-year revenue forecast at $16.5 billion to $16.85 billion.